| Literature DB >> 34440695 |
Paulina Wigner1, Radosław Grębowski2,3, Michal Bijak4, Janusz Szemraj3, Joanna Saluk-Bijak1.
Abstract
Urolithiasis is the third most common urological disease after urinary tract infections and prostate diseases, and it is characterised by an occurrence rate of about 15%, which continues to rise. The increase in the incidence of kidney stones observed in recent decades, is most likely caused by modifications in dietary habits (high content of protein, sodium and sugar diet) and lifestyle (reduced physical activity) in all industrialised countries. Moreover, men are more likely than women to be diagnosed with kidney stones. A growing body of evidence suggests that inflammation, oxidant-antioxidant imbalance, angiogenesis, purine metabolism and urea cycle disorders may play a crucial role in nephrolithiasis development. Patients with urolithiasis were characterised by an increased level of reactive oxygen species (ROS), the products of lipid peroxidation, proinflammatory cytokines as well as proangiogenic factors, compared to controls. Furthermore, it has been shown that deficiency and disorders of enzymes involved in purine metabolism and the urea cycle might be causes of deposit formation. ROS generation suggests that the course of kidney stones might be additionally potentiated by inflammation, purine metabolism and the urea cycle. On the other hand, ROS overproduction may induce activation of angiogenesis, and thus, allows deposit aggregation.Entities:
Keywords: angiogenesis; inflammation; nephrolithiasis; oxidative stress; purine metabolism; urea cycle
Mesh:
Substances:
Year: 2021 PMID: 34440695 PMCID: PMC8393760 DOI: 10.3390/cells10081926
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Under conditions of homeostasis, reactive oxygen radicals are released in amounts safe for the cell and can induce cell differentiation and apoptosis, influence the synthesis, release or inactivation of nitric oxide, and stimulate glucose transport to cells. By increasing the permeability of the capillary walls, they ensure the proper course of the inflammatory reaction. One of the most important tasks performed by ROS is the regulation of the processes of signal transmission from cell to cell and within it. Higher concentrations of these molecules cause toxic cell damage, leading to their destruction. The harmful effect of free oxygen radicals is manifested, among others, by their ability to oxidise proteins, nucleic acids and lipids [51].
Potential biomarkers in kidney stone diagnostics.
| Compound (Abbreviation) | Physiological Role | Disfunction in the Nephrolithiasis Course | Biological Samples | Citations |
|---|---|---|---|---|
| α-tocopherol | A type of vitamin E that has antioxidant capacity to reduce lipid peroxidation. | Reduced level | Serum | [ |
| 8-hydroxydeoxyguanosine (8-oxoG) | An oxidised derivative of deoxyguanosine and is one of the major products of DNA oxidation. | Increased level | Urine | [ |
| Nitrotyrosine | Tyrosine nitration product mediated by reactive nitrogen species, including peroxynitrite anion and nitrogen dioxide. | Increase level | Renal cortex and medulla imply | [ |
| Epithelial nitric oxide synthetase (eNOS) and inducible nitric oxide synthetase (iNOS) | NOSs are a family of enzymes that catalyses the production of nitric oxide from L-arginine. iNOS is in the cytosol, while eNOS is membrane-associated. | Decrease in epithelial eNOS expression and increase in iNOS expression | Renal medulla | [ |
| These are common carotenoids that form retinol and its antioxidant capacity to reduce lipid peroxidation. | Reduced level | Serum | [ | |
| Superoxide dismutase (SOD) | An enzyme catalysing the dismutation of the superoxide radical into ordinary molecular oxygen and hydrogen peroxide. | Reduced activity | Serum | [ |
| Glutathione-S-transferase | An enzyme catalysing the conjugation of the reduced form of glutathione (GSH) to xenobiotic substrates for the purpose of detoxification. | Reduced activity | Serum | [ |
| Glutathione peroxidase (Gpx) | An enzyme that protects the organism from oxidative damage. It reduces lipid hydroperoxides to their corresponding alcohols as well as free hydrogen peroxide to water. | Reduced activity | Serum | [ |
| Malonyl dialdehyde (MDA) | A marker of lipid peroxidation of polyunsaturated fatty acids, including arachidonic acid. | Increased level | Urine | [ |
Figure 2Initiation of “chemokine to cytokine to chemokine” cascade. Kidney stones may contain appreciable amounts of endotoxin, and can stimulate tubular epithelial to secrete chemokines, including IL-8/CXCL8, RANTES/CCL5 and MCP-1/CCL2, via TLR4. IL-8/CXCL8 plays a key role in the recruitment of neutrophils, while RANTES/CCL5 is known for leukocyte recruitment to an inflammatory site. In turn, MCP-1/CCL2 recruits monocytes, memory T cells, NK cells, and induces IL-6 and expresses intercellular adhesion molecule-1 secretion by tubular epithelial cells. Moreover, activated NK cells release IFN-γ, which can stimulate resident tissue cells to produce IP-10/CXCL10 and Mig/CXCL9, which are ultimately responsible for guiding activated T cells back into the inflamed tissues. Thus, stone-induced renal damage can initiate a “chemokine to cytokine to chemokine” cascade, which may play a crucial role in urolithiasis pathogenesis [86,87,88,89,90,91,92,93].
Potential biomarkers associated with inflammation in kidney stone diagnostics.
| Mediator (Abbreviations) | Physiological Role | Disfunction in the Nephrolithiasis Course | Biological Samples | Citations |
|---|---|---|---|---|
| Interleukin 6 | IL-6 is a potent inducer of the acute phase response. Rapid production of IL-6 contributes to host defence during infection and tissue injury, but excessive IL-6 synthesis is involved in disease pathology. In the innate immune response, it is synthesised by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (probable). In the adaptive immune response, it is required for the differentiation of B cells into immunoglobulin-secreting cells. It plays a major role in the differentiation of CD4+ T cell subsets, is an essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-centre formation, is required to drive naive CD4+ T cells to the Th17 lineage. It is also required for proliferation of myeloma cells and the survival of plasma blast cells. | Increase level | Urine | [ |
| Elevated mRNA expression | Kidney tissue | [ | ||
| Monocyte chemoattractant protein 1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) | MCP-1, known as CCL2, is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. | Elevated mRNA expression | Kidney tissue | [ |
| Increased level | Urine | [ | ||
| C-reactive protein (CRP) | An acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells. | Increased level | Serum | [ |
| Interleukin 8/chemokine (C-X-C motif) ligand 8 (IL-8/CXCL8) | IL-8, known also as CXCL8, is a chemokine produced by macrophages, epithelial cells, airway smooth muscle cells and endothelial cells. It induces chemotaxis in neutrophils and other granulocytes, causing them to migrate toward the site of infection. IL-8 also stimulates phagocytosis once they have arrived. IL-8 is also known to be a potent promoter of angiogenesis. | Increased level | Urine | [ |
| Regulated on activation, normal T-cell expressed and secreted/C-C motif chemokine ligand 5 (RANTES/CCL5) | CCL5, known also as RANTES, is chemotactic for T cells, eosinophils, and basophils, and plays an active role in recruiting leukocytes into inflammatory sites. With the help of particular cytokines (i.e., IL-2 and IFN-γ) that are released by T cells, CCL5 also induces the proliferation and activation of certain natural-killer (NK) cells to its activated form. | Increased level | Urine | [ |
| Monokine induced by gamma/chemokine (C-X-C motif) ligand 9 (Mig/CXCL9) | Mig, also known as CXCL9, plays a role in the induction of chemotaxis, promotes differentiation and multiplication of leukocytes, and causes tissue extravasation. | Increased level | Urine | [ |
| C-X-C motif chemokine ligand 10/interferon gamma-induced protein (IP-10/CXCL10) | CXCL10, also known as IP-10, is secreted by monocytes, endothelial cells and fibroblasts in response to IFN-γ. CXCL10 is involved in the chemoattraction for monocytes/macrophages, T cells, NK cells, and dendritic cells, promotion of T cell adhesion to endothelial cells, antitumour activity, and inhibition of bone marrow colony formation and angiogenesis. | Increased level | Urine | [ |
| Chemokine (C-C motif) ligands 4/Macrophage inflammatory protein-1β (CCL4/MIP-1β) | CCL4, also known as MIP-1β, is produced by: neutrophils, monocytes, B cells, T cells, fibroblasts, endothelial cells, and epithelial cells. It is a chemoattractant for natural killer cells, monocytes, and a variety of other immune cells. | Increased level | Urine | [ |
| Interleukin 13 | IL-13 is a cytokine secreted by T helper type 2 cells, CD4 cells, natural killer T cell, mast cells, basophils, eosinophils. It is a central regulator in IgE synthesis, goblet cell hyperplasia, mucus hypersecretion, airway hyperresponsiveness, fibrosis and chitinase up-regulation as well as a mediator of allergic inflammation and different diseases, including asthma. | Increased level | Urine | [ |
Figure 3Purine metabolism includes three steps: de novo synthesis, salvage and breakdown pathways. The de novo synthesis is a multi-step process and requires the contribution of PRPS, four amino acids, one PRPP, two folates and three ATP to synthesise an inosine monophosphate (IMP). IMP may be directly catalysed into inosine by 5′-nucleotidases (5′NT), and then purine nucleoside phosphorylase (PNP) converts inosine into hypoxanthine. HPRT catalyses the salvage synthesis of inosine monophosphate (IMP) and guanosine monophosphate (GMP) from the purine bases hypoxanthine and guanine respectively, utilising PRPP as a co-substrate. The HPRT action causes the accumulation of hypoxanthine and guanine, which are converted into uric acid by XO and xanthine dehydrogenase (XDH) in the breakdown pathway. Additionally, APRT catalyses the salvage synthesis of adenosine monophosphate (AMP) and IMP adenine, utilising PRPP as a co-substrate [106].
Potential biomarkers associated with purine metabolism pathway in kidney stone diagnostics.
| Factor (Abbreviation) | Physiological Role | Disfunction in the Nephrolithiasis Course | Biological Samples | Citations |
|---|---|---|---|---|
| Adenine phosphoribosyl transferase (APRT) | This enzyme is involved in the nucleotide salvage pathway, providing an alternative to nucleotide biosynthesis de novo in humans. | Deficiency | - | [ |
| Hypoxanthine-guanine phosphoribosyltransferase (HPRT) | An enzyme that catalyses conversion of hypoxanthine to inosine monophosphate as well as guanine to guanosine monophosphate. This enzyme plays a crucial role in the generation of purine nucleotides by the purine salvage pathway. | Deficiency | - | [ |
| Xanthine oxidase (XO) | This enzyme is involved in the generation of ROS. It catalyses the oxidation of hypoxanthine to xanthine and can further catalyse the oxidation of xanthine to uric acid. | Deficiency | - | [ |
| Phosphoribosylpyrophosphate synthetase (PRPS) | An enzyme that catalyses the synthesis of phosphoribosyl pyrophosphate (PRPP), an intermediate in nucleotide metabolism and the biosynthesis of the histidine and tryptophan. | Increased activity | - | [ |
| Uric acid | A product of the metabolic breakdown of purine nucleotides, and it is a normal component of urine. | Low level | Plasma | [ |
| Oxy-purines | Oxygenated forms of purines. | Increased level | Plasma | [ |
| Xanthine and Hypoxanthine | Xanthine is a purine base and generated on the pathway of purine degradation. It is formed from oxidation of hypoxanthine by xanthine oxidoreductase. Hypoxanthine is a spontaneous deamination product of adenine. | Increased concentrations | Plasma, | [ |
Figure 4The urea cycle includes five reactions localised at mitochondria of hepatocytes and cytoplasm. The first step involves the CO and ammonia conversion into carbamoyl phosphate via carbamoyl phosphate synthetase I (CPS I). Carbamoyl phosphate and ornithine (whose elevated plasma level and decreased urine level are observed in patients with nephrolithiasis) combine to citrulline via ornithine transcarbamoylase (OTC). Then ornithine translocase transports citrulline from hepatocyte mitochondria into the cytoplasm. Citrulline reacts with aspartate and argininosuccinate forms. This reaction is catalysed by argininosuccinate synthetase (ASS). Argininosuccinate is converted into arginine via argininosuccinate lyase (ASL). Finally, arginase (ARG1) hydrolyses arginine into urea and ornithine. On the other hand, L-arginine may be oxidatively degraded by NOS into L-citrulline and nitric oxide (NO). In the course of nephrolithiasis, a decrease in eNOS expression has been observed. Moreover, ornithine from the urea cycle may be converted by ornithine decarboxylase (ODC) in the polyamine biosynthetic pathway. ODC polymorphism may be associated with an increased risk of kidney stones [115].